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gd T cells bridge innate and adaptive immunity and
function in immunosurveillance, immunoregulation,
tumor cell recognition, and as first line of defense
against microbial infection. Costimulation of epithe-
lial gd T cell activation by the JAML receptor can be
induced by interaction with its endogenous ligand
CAR or by binding of the stimulatory antibody
HL4E10. We, therefore, determined the crystal struc-
ture of the JAML-HL4E10 Fab complex at 2.95 A˚
resolution. HL4E10 binds the membrane-proximal
domain of JAML through hydrophobic interactions
that account for nanomolar affinity and long half-
life, contrasting with the fast kinetics andmicromolar
affinity of the hydrophilic CAR interaction with the
membrane-distal JAML domain. Thus, despite
different binding sites and mechanisms, JAML inter-
action with these two disparate ligands leads to the
same functional outcome, namely JAML triggering
and induction of cell signaling. Several characteris-
tics of the HL4E10 antibody might then be harnessed
in therapeutic applications, such as promoting heal-
ing of acute or chronic wounds.
INTRODUCTION
Dendritic epidermal gd T cells (DETCs) residing in the skin are
prototypical intraepithelial lymphocytes (Jameson et al., 2004)
with a unique dendritic morphology (Boismenu and Havran,
1998). As the only resident T cell population in the epidermis,
DETCs are key players in tissue homeostasis, including tumor
surveillance and wound repair (Jameson et al., 2002, 2003,
2004; Sharp et al., 2005). DETCs use an invariant T cell receptor
(TCR) to bind unknown self-antigens expressed by neighboring
cells during biological insults including infection, trauma or
malignancy (Jameson et al., 2003, 2004). Recent evidence
suggests that for activation and for production of rapid and
robust effector functions, epithelial gd T cells, like ab T cells,
require accessory molecules to enhance the TCR-mediated
signals (Witherden et al., 2010).80 Structure 19, 80–89, January 12, 2011 ª2011 Elsevier Ltd All rightIn ab T cells, accessory molecules are utilized for modulating
antigen responses and for the differentiation of T cells into
phenotypically distinct effector cells. Costimulatory signals are
important for clonal expansion and protective immune response,
while inhibitory signals maintain T cell self-tolerance and prevent
autoimmunity (Croft, 2003; Kroczek et al., 2004; Salomon and
Bluestone, 2001; Sharpe and Freeman, 2002; Watts, 2005).
Thus, manipulation of immune modulatory interactions holds
considerable promise in the clinic (Abken et al., 2002; Chambers
et al., 2001; Martin-Orozco and Dong, 2006; Snanoudj et al.,
2006; Stuart and Racke, 2002; Vincenti and Luggen, 2007;
Weaver et al., 2008; Zang and Allison, 2007).
The importance of accessory molecules for activation of
gd T cell responses has only recently been established (Whang
et al., 2009; Witherden et al., 2010). Consistent with their
distinct function, DETCs do not express the ab T cell corecep-
tors CD4 and CD8, or the costimulatory molecules CD28
and ICOS, which are essential for ab T cell function (Boismenu
and Havran, 1998; Haas et al., 1993; Jameson et al., 2004;
Shires et al., 2001). Instead, the Junctional Adhesion Mole-
cule-Like protein, JAML (Moog-Lutz et al., 2003), was identified
as the first costimulatory receptor specific to epithelial
gd T cells (Witherden et al., 2010). The interaction of JAML
with Coxsackie and Adenovirus receptor, CAR (Bergelson
et al., 1997; Guo et al., 2009; Luissint et al., 2008; Verdino
et al., 2010a; Zen et al., 2005) on keratinocytes, or with the
stimulatory HL4E10 IgG antibody (Ab), induces potent costimu-
lation, cytokine and growth factor production, and activation of
MAP kinase pathways. This stimulation ultimately leads to
increased DETC proliferation, and is important for modulating
gd T cell responses during epithelial challenges, such as wound
repair (Witherden et al., 2010).
Interestingly, HL4E10 elicits the same gd T cell responses as
the natural ligand CAR, but does not compete with CAR for
JAML binding (Witherden et al., 2010). Furthermore, HL4E10
can restore JAML-mediated costimulation of skin gd T cells
following blockage of CAR and, thus, reestablish proper wound
healing (Witherden et al., 2010). Given the promising results of
manipulating immune modulatory interactions of ab T cells,
humanized versions of HL4E10 might find application in the
treatment of gd T cell-associated diseases including chronic
non-healing wounds. To gain a deeper understanding of the
mechanisms of Ab-induced gd T cell costimulation, we investi-
gated the molecular, functional, and structural characteristicss reserved
Table 1. JAML-HL4E10 Fab Complex Data Collection and
Refinement Statistics
Data Collection
Space group P43212
Cell dimensions
a, b, c (A˚) 125.0, 125.0, 107.8
Wavelength (A˚) 0.9793
Resolution (A˚) 30.00–2.95 (3.06–2.95)a
Rmerge (%) 12.2 (61.7)
<I / sI > 6.8 (1.8)
Completeness (%) 97.7 (99.0)
Unique reflections 18,365 (1816)
Redundancy 3.1 (2.9)
Refinement
Resolution (A˚) 30.00–2.95
No. reflections work / test 17,200/927
Rcryst/Rfree (%) 22.5/28.7
No. atoms
JAML 1841
Carbohydrates 99
HL4E10 light chain 1575
HL4E10 heavy chain 1579
B-values (A˚2)
JAML 72
Carbohydrates 75
HL4E10 light chain 74
HL4E10 heavy chain 73
Rmsd
Bond lengths (A˚) 0.006
Bond angles () 1.1
Ramachandran plot (%)
Favored /allowed/outliers 94.2/5.5/0.3b
aHighest resolution shell is given in parentheses.
b TyrH97 and ProH149 are the only residues in the disallowed region, but are
both located in loops with well-defined electron density.
Structure
Structure of the JAML-HL4E10 Antibody Complexof the HL4E10-JAML complex and compared those with the
endogenous CAR-JAML interaction.
The JAML-HL4E10 complex crystal structure reveals that
the antibody HL4E10 binds the membrane-proximal domain
of JAML through hydrophobic interactions that account for
nanomolar affinity and long half-life in contrast to the extremely
hydrophilic interaction of the natural ligand CAR with the
membrane-distal domain of JAML which displays fast kinetics
and only micromolar affinity. However, HL4E10 and CAR
both induce JAML triggering, cell signaling through PI3K,
and gd T cell proliferation. Our findings support ligand-induced
JAML dimerization/clustering as the mechanism for receptor
triggering that, in the case of the natural ligand, may be initiated
by increased CAR expression. Furthermore, several characteris-
tics of the HL4E10 antibody appear favorable for therapeutic
applications, including its ability to elicit gd T cell responses
indiscernible from those of the endogenous ligand CAR without
interfering with the normal JAML-CAR interaction, as well as the
high affinity, high specificity and long half-life of the antibody-
receptor interaction.
RESULTS
Crystal Structure Determination of the JAML-HL4E10
Fab Complex
The entire glycosylated mouse JAML ectodomain (residues 1–
260) was produced in SC2 cells essentially as described (Verdino
et al., 2010). The HL4E10 Fab was obtained by pepsin digestion
and reduction of hamster anti-JAML IgG (l) HL4E10 produced in
a hybridoma cell line. The JAML-HL4E10 Fab complex was
prepared for structural studies by incubating JAML with excess
HL4E10 Fab and subsequent purification of the complex by
size exclusion chromatography. Crystals were obtained and
a complete data set to 2.95 A˚ resolution was collected at the
Advanced Photon Source beamline 23ID-D (Argonne National
Laboratory, Chicago, IL). The structure was determined by
molecular replacement in tetragonal space group P43212 using
unliganded structures of JAML (PDB entry 3MJ6) and the
HL4E10 Fab (3MJ8) as templates and refined to Rcryst = 22.5%
and Rfree = 28.7%. The final model consists of JAML residues
Val8-Asp236 (residues 1–7, which correspond to the A-strand
of the D1 Ig domain, and residues 237–260, which compose
the C-terminal stalk that links the Ig domains to the cell
membrane, as well as the C-terminal His6-tag, were not visible
in the electron density maps), N-acetylglucosamine residues
linked to Asn59 and to Asn69, and, due to crystal packing,
a very well-defined, N-linked carbohydratemoiety (twoN-acetyl-
glucosamines, one fucose, three mannoses) linked to Asn105.
The HL4E10 Fab light chain consisted of TyrL2-SerL212, and the
heavy chain of GlnH1-GlyH228 (Table 1).
Molecular Structure of the JAML-HL4E10 Fab Complex
Consistent with biochemical binding studies (Witherden et al.,
2010), the JAML-HL4E10 complex crystal structure revealed
that HL4E10 Fab binds the membrane-proximal, D2 Ig domain
of JAML (Figure 1). All six Fab CDRs (L1-3, H1-3) interact with
the C-terminal JAML D2 domain and bury 1600 A˚2 of the
molecular surface area (820 A˚2 on HL4E10 and 780 A˚2 on
JAML). The area and the shape complementarity (Sc = 0.66;Structure 19,Lawrence and Colman, 1993) of the interface are comparable
to those of typical antibody/antigen complexes (Lo Conte
et al., 1999). Approximately 50% of the buried HL4E10 surface
area (420 A˚2 out of 820 A˚2) is contributed by aromatic residues
(34% tyrosine, 10% tryptophan, 7% phenylalanine) (Figures 2
and 3). In addition, eight scattered HL4E10 framework residues
contact the JAML D1 BC-loop and bury 230 A˚2 surface areas
on both, HL4E10 and JAML (Figure 1).
The HL4E10 CDRs contact the BC-, C0C00-, and DE-loops of
the JAML D2 Ig domain. The key feature of this interaction is
the insertion of CDR H3 between two b sheets, GFCC0C00 and
BED, of the JAML Ig-fold. While PheH96, TyrH97, TyrH99, and
TyrL32 of the Fab are inserted into a cleft in the D2 domain of
JAML, TrpL91 and TrpL96 of CDR L3 contribute additional hydro-
phobic contacts with the JAML C0C00-loop (Figures 2 and 3).
A total of 170 interactions are formed between JAML and
HL4E10: 154 van der Waals contacts, 15 H-bonds, and a salt
bridge between AspH101 (CDR H3) and JAML Lys146. TyrH97 in80–89, January 12, 2011 ª2011 Elsevier Ltd All rights reserved 81
Figure 1. The Stimulatory HL4E10 Antibody Binds the C-Terminal,
Membrane-Proximal JAML D2 Ig Domain
Ribbon representation of the JAML-HL4E10 Fab complex. JAML and its two
variable Ig domains are shown in light blue for the membrane-distal,
N-terminal, D1 domain (residues 8–121) and in salmon for the membrane-
proximal, C-terminal, D2 domain (residues 122–236). The JAML D1 A-strand
(residues 1–7) and the C-terminal stalk region (residues 234–260, salmon
dashes), which tethers the JAML Ig domains to the cell membrane, were disor-
dered. Carbohydrate moieties attached to the three N-linked glycosylation
sites (Asn59, Asn69, and Asn105) are shown in stick representation. The Fab
fragment of the HL4E10 IgG is shown in gray for the light chain (variable
domain VL and constant domain CL, residues 2–212) and dark gray for the
heavy chain (variable domain VH and constant domain CH1, residues 1–228).
All six Fab CDRs contact JAML (CDR L1, yellow; L2, cyan, L3, red; H1, blue;
H2, pink; H3, green). The interaction of HL4E10 is focused on the C-terminal
JAML D2 domain, in particular on the C0C00-loop, the D-strand, the DE-loop,
and the BC-loop. CDR H3 is inserted between the JAML A0GFCC0C00 and
BED sheets and locks the JAML C0C00-loop and the C00-strand, which has un-
raveled from the b sheet of the Ig-fold, into a conformation strikingly distinct
from that found in the crystal structure of unliganded JAML.
Structure
Structure of the JAML-HL4E10 Antibody ComplexCDR H3 appears to be the key contributor to the JAML-HL4E10
interaction. Its side chain is deeply inserted into a pocket
between the JAML C0C00 and DE loops (Figure 2) and contributes
62 van der Waals contacts (36% of all HL4E10 contacts with
JAML), as well as two H-bonds from its hydroxyl group to the
main chain of two deeply buried JAML residues, Val148 and
Lys150 (Figure 3B).HL4E10 Binds a Conformationally Flexible Region
of JAML
No significant conformational changes occur in HL4E10 upon
complex formation (rmsd of 0.7 A˚ for superimposition of the82 Structure 19, 80–89, January 12, 2011 ª2011 Elsevier Ltd All rightbackbone atoms of the variable domains of complexed
HL4E10 and unliganded HL4E10; PDB 3MJ8). In contrast, the
JAML region which constitutes the HL4E10 binding site
adopts a strikingly different conformation in the JAML-HL4E10
complex as compared to unliganded JAML (PDB 3MJ6) (Verdino
et al., 2010), whereas the rest of JAML is essentially unchanged
(backbone atom rmsd of 1.1 A˚ for entire JAML; 1.1 A˚ for D1, 1.0 A˚
for D2). In the JAML-HL4E10 complex, JAML Asn172-Leu181
(C0C00-loop) and the C00-strand exhibit an average rmsd of 4.0 A˚
and the Phe178 side chain undergoes an 11 A˚ movement
(Figure 4A), mostly due to interaction with CDRs H3 and L3.
Additionally, the N-terminal portion of the JAML C00-strand
(Gly176-Phe178) peels away from the b sheet and extends the
C0C00-loop (Figures 1 and 4). Disruption of the b sheet structure
accompanies movement of the C00-strand toward the HL4E10-
binding site, and disrupts the normal b sheet H-bonds observed
between the C0- and C00-strands. Instead of four standard,
b sheet H-bonds in unliganded JAML, the conformational
change and a register shift results in Ser168 in the C0-strand H
bonding with Gln179 (rather than Phe178) in the C00-strand in
the JAML-HL4E10 complex (Figure 4B).
In the crystal structure of unliganded JAML (PDB 3MJ6) (Ver-
dino et al., 2010), the region which constitutes the binding site
for HL4E10 exhibits elevated average B-values (46 A˚2) as
compared with the rest of JAML (36 A˚2), indicative of increased
conformational flexibility. Thus, the C00- and D-strands of the
JAML D2 domain appear to be sampling a variety of conforma-
tions in the unbound form and, upon HL4E10 binding, are locked
into a distinct conformation, which contrasts to some extent with
the general perception of Ig domain b sandwich scaffolds as
fairly rigid molecular structures.
HL4E10 and CAR Interact with Distinct Binding Kinetics
and Affinities with Different JAML Domains, but Induce
Comparable PI3K Recruitment and DETC Proliferation
To further explore similarities and differences in the interaction of
HL4E10 and CAR with the membrane-proximal and membrane-
distal JAML domains, respectively (Figure 5), binding kinetics
and affinities of the respective JAML-ligand complexes were
investigated by SPR (Figure 6; see Figure S3 available online).
HL4E10 Fab binds surface-immobilized JAMLwith a fast on-rate
(Kon 1.3 3 105 M-1s-1) and a slow off-rate (Koff 0.001 s-1)
resulting in a half-life of the interaction in the order of 10 min.
In contrast, the JAML-CAR interaction is characterized by
a fast on-rate (Kon 1 3 105 M-1s-1) and a biphasic dissociation
where the majority of CAR dissociates rapidly (Koff 0.5 s-1)
with an estimated half-life of 1 s and the rest dissociates
more slowly. A similar biphasic dissociation pattern has previ-
ously been observed for the CD2-CD48 interaction and been
attributed to small amounts of multimeric aggregates in the
sample (van der Merwe et al., 1993). The binding affinities of
the two JAML complexes differ by about three orders of magni-
tude, with a KD of 8 nM for JAML-HL4E10 and 3–6 mM for
JAML-CAR.
HL4E10 and CAR induce potent costimulation of DETCs
through cytokine and growth factor production and activation
of MAP kinase pathways (Witherden et al., 2010) and binding
of phosphoinositide-3-kinase (PI3K) to the JAML intracellular
domain (ICD) is a key component in JAML signaling. Consistents reserved
Figure 2. The JAML-HL4E10 Complex Is Characterized by Extensive Hydrophobic Interactions
Molecular surface of JAML with the HL4E10 epitope colored in yellow (CDR L1 contacts), cyan (CDR L2), red (CDR L3), blue (CDR H1), magenta (CDR H2), and
green (CDR H3). In the detail shown on the right, the electrostatic potential was mapped onto the molecular surface of JAML and contoured at ±60 kT/eV (blue/
red). HL4E10 residues contacting JAML are shown as sticks above the JAML surface. The JAML-HL4E10 interface is noticeably hydrophobic and dominated by
van der Waals’ interactions between aromatic HL4E10 (TyrL32, TyrL49, TrpL91, TrpL96, TyrH32, PheH96, TyrH97, TyrH99) and hydrophobic JAML residues (Val148,
Met173, Phe178, Tyr169, Ile194, Leu190). Surprisingly, 36% of all HL4E10 contacts with JAML are contributed by only one residue, TyrH97, which is deeply in-
serted into a hydrophobic pocket in the JAML D2 domain (black arrow).
Structure
Structure of the JAML-HL4E10 Antibody Complexwith their comparable fast on-rates, HL4E10 and CAR both
induce rapid PI3K association within 1 min after JAML ligation
that is sustained for up to 30 min (Figure 7A). It has been shown
that, in solution, only ligation by dimeric/multivalent ligands (such
as a bivalent CAR-Fc fusion construct or intact HL4E10 IgG), but
not monomeric ligands, leads to PI3K recruitment to JAML (Ver-
dino et al., 2010). However, when immobilized to a surface,
monomeric HL4E10 Fab and CAR-His induce similar levels of
DETC proliferation as dimeric JAML ligands (Figure 7B).The High Specificity of the JAML-CAR Interaction
Is Evolutionary Conserved
Sequence conservation analysis reveals that JAML and CAR
homologs are found in mammals and other vertebrates including
fowl (Figures S1 and S2). The evolutionary more ancient JAMLs
from opossum, platypus, and chicken contain only the
N-terminal, CAR-binding D1 Ig domain (Figure S1), while JAML
of placental mammals contains an additional D2 Ig domain.
Several features, including 44% sequence identity with D1,
suggest that D2 arose from domain duplication. For CAR, the
overall domain structure and entire sequence is highly
conserved among species (Figure S2) (Carson, 2001; Coyne
and Bergelson, 2005; Freimuth et al., 2008; Howitt et al.,
2003). Notably, the charged residues that provide high speci-
ficity to the JAML-CAR interaction are conserved among all
JAML and CAR homologs suggesting that these charged
residues are crucial for the physiological function of this
receptor-ligand pair.Structure 19,DISCUSSION
The stimulatory Ab HL4E10 and the endogenous natural ligand
CAR use entirely different receptor-binding mechanisms to
induce JAML-mediated costimulation of epithelial gd T cell acti-
vation. The Ab and CAR elicited gd T cell responses, including
activation of kinase cascades, cytokine production, and cell
proliferation, are comparable (Witherden et al., 2010), yet the
interactions of HL4E10 and CAR with JAML are completely
distinct. First, HL4E10 binds the membrane-proximal JAML D2
domain, while CAR binds the membrane-distal JAML D1
domain. Second, while the total buried surface areas and shape
complementarities are comparable (JAML-HL4E10: 1605 A˚2,
Sc = 0.66; JAML-CAR: 1460 A˚2, Sc = 0.64), the composition of
the JAML-HL4E10 and JAML-CAR interfaces are remarkably
different: the former is dominated by hydrophobic interactions,
while the latter is exceptionally hydrophilic due to numerous
charged residues that engage in an interdigitating salt bridge
network (Verdino et al., 2010). Third, the different receptor-ligand
interactions are reflected in distinct binding kinetics and three
orders of magnitude difference in affinity.
Based on their fundamentally different modes of interaction
with JAML, the central question arises as to how both ligands
are able to induce essentially identical gd T cell responses
through JAML engagement? Moreover, how do these findings
impact our understanding of JAML receptor function and, thus,
the molecular mechanism of epithelial gd T cell costimulation?
The fact that HL4E10 and CAR bind different JAML Ig domains
indicates that binding to the physiological receptor binding site80–89, January 12, 2011 ª2011 Elsevier Ltd All rights reserved 83
Figure 3. Closeup Stereo Representation of
the JAML-HL4E10 Interaction
Insertion of HL4E10 CDR L1 and H3 into the cleft
between JAML C0C00- and DE-loops. The Fab
CDR loops are color-coded (CDR L1, yellow; L2,
cyan, L3, red; H1, blue; H2, pink; H3, green) and
JAML is shown in gray. (A) The 2Fo-Fc electron
density around the interacting residues is con-
toured at 1s (light blue mesh). (B) Note the tyro-
sines that are engaged in hydrophobic stacking
and hydrogen bonds via their polar hydroxyl
groups. For example, TyrH97 of HL4E10 CDR H3
is packed against Tyr169 and Ile194 and the
main chain of Asp170 and Ser171, and hydrogen
bonds to the backbone carbonyl of Val148 and
the amide of Lys150. Similarly, JAML Tyr169
stacks against HL4E10 TyrH97 and TyrL32 and
hydrogen bonds with ThrH98 and GluL50.
Structure
Structure of the JAML-HL4E10 Antibody Complexon the D1 domain is not the only mode of binding and mecha-
nism that can elicit receptor triggering. While the C00- and
D-strands of the JAML D2 domain adopt different conformations
in unliganded JAML and the JAML-HL4E10 complex, these
differences appear to be a reflection of the inherent conforma-
tional flexibility of this particular region in JAML rather than
a specific signaling mechanism, especially as it is difficult to
envision how such changes could relay a signal along the flexible
C-terminal stalk to the ICD. Furthermore, no significant structural
rearrangements were observed upon CAR-binding to JAML
(Verdino et al., 2010), also suggesting a mechanism for JAML
receptor triggering that is not caused by conformational
changes.
Receptor crosslinking/clustering is a common mechanism of
signal transduction in cell surface receptors including receptor
tyrosine kinases or cytokine receptors (for review, see Lemmon
and Schlessinger, 1998; Schlessinger, 2000). For JAML, it has
been shown that binding of bivalent, but not monovalent, ligands
induces recruitment of phosphoinositide-3-kinase (PI3K) to
the JAML ICD and subsequent cell signaling (Verdino et al.,
2010). Furthermore, the crystal structure of the JAML-CAR
ectodomain complex revealed dimerization of the JAML-CAR
complex that is mediated by interaction of two adjacent
CAR molecules (Verdino et al., 2010). The JAML-HL4E10 Fab
structure does not contain any higher order oligomeric assem-
blies, consistent with the inability of monovalent HL4E10 Fab
to induce PI3K recruitment in solution. However, if the Fab frag-
ment is immobilized to a surface, it acts like a ‘‘quasimultivalent’’84 Structure 19, 80–89, January 12, 2011 ª2011 Elsevier Ltd All rights reservedligand and induces potent DETC prolifer-
ation comparable to that of intact bivalent
HL4E10 IgG. These findings thus strongly
support ligand-induced, JAML dimeriza-
tion/clustering as a receptor triggering
mechanism.
Expression profiles and the character-
istics of the JAML-CAR interaction also
suggest that JAML acts as a sensor on
the DETC surface that is activated by
clustering induced by increased CAR
expression. First, JAML is constitutivelyexpressed at low levels on DETCs and is upregulated upon
cellular activation (Witherden et al., 2010). Likewise, surface
expression of CAR has been shown to be modified by inflamma-
tion, by noninflammatory responses to tissue damage, by influ-
ence of neighboring cells (Carson, 2001; Freimuth et al., 2008)
and is increased on stressed keratinocytes (Witherden et al.,
2010). Second, the hydrophilic nature of the CAR epitope on
JAML likely aids in JAML stability and solubilization on the cell
surface in the absence of ligand. Third, the high specificity and
fast kinetics of the JAML-CAR ectodomain interaction ensure
a sensitive, rapid cellular JAML response to ligand binding that
is also reflected by the fast association and dissociation of
PI3K on the JAML ICD (Verdino et al., 2010).
These findings all support the current view of skin gd T cells as
first responders to cellular stress that exhibit effector functions
rapidly after biological or physical insult (Hayday, 2009). While
the semiactivated state of skin gd T cells enables rapid
responses without significant delays (for example, due to clonal
expansion), the powerful consequences of their full activation,
such as inflammation and cytolysis, require tight control mecha-
nisms. Costimulatory receptor-ligand pairs, such as JAML and
CAR, which determine the final outcome of the primary TCR-
ligand interaction, constitute an ideal checkpoint. The constitu-
tive expression of JAML ensures high sensitivity and fast
responses, while the pronounced specificity provided by the
charge-complementary interface reduces the likelihood of false
triggering. The striking conservation of the complementary
charged residues in the JAML-CAR interface, even in the
Figure 4. HL4E10 Binds to a Conformation-
ally Flexible Region of JAML
Wall-eyed stereo representation of the different
conformations of the HL4E10 epitope of unli-
ganded JAML (3MJ6, gray) and HL4E10-bound
JAML (3MJ9, red). Residues are labeled in one
letter code for unliganded JAML.
(A) View of the HL4E10 epitope of JAML from the
Ab perspective. The JAML C0C00-loop undergoes
up to 7 A˚ backbone shifts and up to 11 A˚ shifts
for side chains.
(B) The JAML C00-strand has lost its b strand char-
acter and moved 3 A˚ toward the C0C00-loop.
Instead of four standard H-bonds between the
C0- and the C00-strand as in unliganded JAML
(gray dashes), only two nonconventional H-bonds
are formed between those strands in the JAML-
HL4E10 complex (red dashes).
Structure
Structure of the JAML-HL4E10 Antibody Complexevolutionary more distant single Ig domain JAML receptors in
non-placental mammals and fowl, also supports this hypothesis.
In ab T cells, manipulation of immune-modulatory receptor
signals as means to treat autoimmune diseases, cancers, and
allograft rejection has become a promising new clinical strategy
(Abken et al., 2002; Chambers et al., 2001; Martin-Orozco and
Dong, 2006; Snanoudj et al., 2006; Stuart and Racke, 2002; Vin-
centi and Luggen, 2007; Weaver et al., 2008; Zang and Allison,
2007). The ability of the HL4E10 IgG to restore JAML-mediated
costimulation of DETCs in the absence of CAR ligation, and to re-
establish proper wound healing, has indicated potential for the
use of HL4E10 derivatives to modulate skin gd T cell responses
in the clinic (Witherden et al., 2010). Our data reveal that HL4E10
might, indeed, be a good candidate for such applications. Signif-
icantly, HL4E10 induces JAML-mediated gd T cell responses
that are indiscernible from those elicited by the natural ligand
CAR (Witherden et al., 2010). However, as the epitope for
HL4E10 is on a different domain from the CAR binding site, no
competition is found with the endogenous JAML-CAR interac-
tion. Thus, HL4E10 is less likely to interfere with CAR-related
signaling in keratinocytes in vivo. As seen for CAR, HL4E10
binding to JAML is characterized by a fast on-rate; however,
the extensive hydrophobic interface result in a500 times longer
half-life for the JAML-HL4E10 complex. PI3K recruitment at the
JAML ICD is tightly linked to the extracellular JAML-CAR interac-
tion (Verdino et al., 2010), where PI3K associates with JAML
within 1 min of CAR binding and dissociates within 1 min afterStructure 19, 80–89, January 12, 201the JAML-CAR interaction has been dis-
rupted. This rapid response seems to be
facilitated by the fast on- and off-rates
of CAR for JAML. Likewise, for the
HL4E10-JAML interaction, the fast on-
rate observed by SPR also coincides
with rapid PI3K recruitment and it is likely
that the long half-life of the complex could
lead to sustained PI3K signaling. Further-
more, the rigid HL4E10 combining site
provides optimal positioning of the key
residues for JAML interaction, including
TyrH97, which deeply protrudes intoa pocket on the JAML D2 surface, and JAML Tyr169 which
inserts into the HL4E10 combining site. These features all
increase specificity and eliminate HL4E10 targeting of unrelated
receptors. Indeed, the high specificity of HL4E10 for JAML has
been demonstrated by lack of cross-reactivity with other Junc-
tional Adhesionmolecules including JAM-A, B, andC (Witherden
et al., 2010).
DETC activation by both HL4E10 and CAR binding critically
depends on suboptimal concentrations of CD3 indicating that
TCR signaling is a prerequisite for JAML-mediated costimula-
tion (Witherden et al., 2010). HL4E10 thus contrasts with Abs
against the major ab T cell costimulatory receptor CD28, where
conventional stimulatory Abs recognize an epitope close to the
binding site for the endogenous ligands, CD80 (B7-1) and CD86
(B7-2), while TCR-independent superagonists bind to a different
epitope located elsewhere (Davis and van der Merwe, 2006;
Evans et al., 2005; Luhder et al., 2003). The dependency of
HL4E10 activity on primary TCR-CD3 signals without interfering
with the natural JAML-CAR interaction might help avoid
the adverse effects elicited by anti-CD28 superagonistic Abs
in clinical trials (Suntharalingam et al., 2006; Waibler et al.,
2008).
Summary
In summary, we demonstrate how JAML-mediated, epithelial
gd T cell activation can be induced by two distinct ligands,
monoclonal Ab HL4E10 and CAR, that use fundamentally1 ª2011 Elsevier Ltd All rights reserved 85
Figure 5. Comparison of JAML-Binding to the Stimulatory HL4E10
Antibody or Its Endogenous Ligand CAR
JAML bound by HL4E10 is superimposed with JAML complexed with CAR
(3MJ7) (N-terminal D1 Ig domain, light green, C-terminal D2 Ig domain, gold,
disordered CAR D2 loops, dots). HL4E10 binds the membrane-proximal
JAML D2 Ig domain (transparent salmon surface) through extensive hydro-
phobic interactions mediated by all six CDR loops. In contrast, CAR binds
the A0GFCC0C00 b sheet of the JAML membrane-distal D1 domain (transparent
light blue surface) via an overwhelmingly hydrophilic interface.
Figure 6. HL4E10 and CAR Interaction with JAML as Observed by
SPR Reveal Distinct Binding Affinities and Kinetics
SPRbinding data of HL4E10 Fab andCAR to immobilized JAML. Injection start
and end points are indicated with red arrows.
(A) HL4E10 Fab (2–500 nM) binding to JAML. Data (colored lines) are overlaid
with a global fitting using a standard 1:1 Langmuir binding isotherm (black
lines). The interaction is characterized by a fast on-rate and slow off-rate,
apparent by the long half-life in the order of 10 min.
(B) CAR (0.3–20 mM) binding to JAML. Data are overlaid with a global fitting
using a complex binding model accounting for heterogeneity of the ligand.
The JAML-CAR interaction exhibits rapid on-and off-rates and a half-life
of 1 s.
See also Figure S3.
Structure
Structure of the JAML-HL4E10 Antibody Complexdifferent receptor-binding mechanisms. Recently, multiple
different Abs against immune-modulatory receptors have
proved successful in tumor immunotherapy, treatment of auto-
immune diseases, or prevention of allograft rejection. Our
studies reveal HL4E10 characteristics that are favorable for
potential use of humanized versions of this antibody in therapy.
Understanding the structure-function relationships of JAML,
CAR, and HL4E10 and their role in immune modulation might
thus aid in the development of novel therapeutics for treatment
of gd T cell related diseases, such as chronic nonhealing
wounds, colitis, and cancer.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The ectodomain of mouse JAML comprising residues 1–260 of the mature
protein including an engineered C-terminal His6-tag and a stop codon was ex-
pressed in SC2 cells, isolated from the supernatant by Ni-NTA affinity chroma-
tography, and purified to homogeneity by size exclusion chromatography as
previously described.
The monoclonal hamster anti-JAML IgG, HL4E10, was isolated from
hybridoma cell supernatants by Protein A chromatography and digested
for 3 hr with 4% pepsin in 1 M Na-acetate (pH 5.5) in the presence of
20 mM cysteine. Fc and undigested IgG were removed by binding to
a Protein A column. The Fab was further purified on Protein G and size exclu-
sion columns. The cDNA sequence of HL4E10 IgG was determined.86 Structure 19, 80–89, January 12, 2011 ª2011 Elsevier Ltd All rightCrystallization, Data Collection, Structure Determination,
and Refinement
The JAML-HL4E10 complex was prepared by incubating JAML with 1.5-fold
stoichiometric excess HL4E10 Fab for 2 hr at 4C in 20 mM Tris-HCl
(pH 8.0), 150 mM NaCl with subsequent purification by size exclusion chro-
matography in the same buffer (Superdex 75 10/30, Amersham Pharmacia
Biotech). Rod-shaped crystals (0.5 3 0.02 3 0.02 mm) were obtained at
22C by mixing 1 ml 6.5 mg/ml JAML-HL4E10 (in 20 mM Tris-HCl [pH 8.0],
150 mM NaCl) with 1 ml 1.2–1.4 M Na-malonate (pH 6.0) by sitting drop
vapor diffusion against 0.5 ml reservoir solution. JAML-HL4E10 complex
data were collected from a single crystal to 2.95 A˚ resolution at the
Advanced Photon Source beamline 23ID-D (Argonne National Laboratory,
Chicago, IL), and integrated and scaled with HKL2000 (Otwinowski and
Minor, 1997).
The unliganded structures of JAML (3MJ6) (Verdino et al., 2010a) and the
HL4E10 Fab (3MJ8) were used as templates for molecular replacement.
Solutions for JAML and the individual variable and constant domains of the
Fab were found with PHASER (McCoy et al., 2005) in tetragonal space group
P43212. The MR model was subjected to rigid body refinement and
restrained all-atom refinement with simulated annealing with CNS (Bru¨nger
et al., 1998), and further improved by alternating cycles of model building
with COOT (Emsley et al., 2010) and refinement with CNS and REFMAC5
(Winn et al., 2001).s reserved
Figure 7. PI3K Recruitment and Induction of DETC Proliferation by
HL4E10 Binding to JAML
(A) Anti-PI3K western blots of JAML immunoprecipitated from epithelial
gd T cell lysates at various time points after stimulation with HL4E10 IgG. After
1 min, PI3K association to JAML is significantly elevated over the basal level.
(B) Costimulation of gd T cell activation through HL4E10 IgG or Fab-binding to
JAML. Proliferation of DETCs to immobilized anti-CD3 IgG either alone
(shaded bars) or in combination with anti-JAML HL4E10 IgG (solid bars),
control IgG 1F4 (open bars), anti-JAML HL4E10 Fab fragment (striped bars),
or control Fab (dotted bars) was assessed by 3H-thymidine incorporation.
HL4E10 IgG and its Fab fragment both induce comparable activation of DETCs
when surface immobilized.
Structure
Structure of the JAML-HL4E10 Antibody ComplexStructure Validation and Analysis
The quality of the structure was verified with WHATCHECK (Hooft et al., 1996)
and MOLPROBITY (overall clash score: 17.99, 95th percentile; Molprobity
score: 2.43, 95th percentile) (Lovell et al., 2003). Root mean square displace-
ments (rmsd) were determined with LSQMAN (Kleywegt, 1996). Hydrogen
bonds were evaluated using HBPLUS (McDonald and Thornton, 1994), and
van der Waals contacts were assigned with CONTACTSYM (Sheriff et al.,
1987). Buried molecular surface areas were determined with MS (Connolly,
1993) with a 1.7 A˚ probe radius and standard van der Waals radii (Gelin and
Karplus, 1979). Shape correlation (Sc) values were calculated with SC (Law-
rence and Colman, 1993). Graphics were prepared with PYMOL (DeLano,
2002).
Surface Plasmon Resonance Experiments
The pMT/BIP/V5-His A JAML expression vector (Verdino et al., 2010) was
used as a template to insert the BirA-tag sequence GGIFEAMKMELRD in
the JAML stalk region between Leu258 and Asn259 with mPIPE cloning (Klock
et al., 2008). The construct was transfected into SC2 cells, and BirA-tagged
JAML was expressed and purified analogously as described for wt JAML (Ver-
dino et al., 2010a). Two milligrams BirA-tagged JAML and a BirA-tagged
control protein (peptide loaded MHC class II) in 50 mM Bicine (pH 8.3) were
biotinylated with 1/30 w/w BirA biotin protein ligase for 20 hr at room temper-
ature according the manufacturer’s protocol (Avidity LLC). Proteins were puri-
fied by size exclusion chromatography (Superdex 75 HR10/30) immediately
prior to performing the SPR experiments. SPRmeasurements were performed
on a BIAcore 2000 (GE Healthcare Inc.) at 25C using 20 mM Tris, 150 mM
NaCl (pH 8.0) as running buffer. JAML and the control protein were captured
in two different flow cells on a BIAcore SA sensor chip. Binding studies were
performed for concentration series of CAR (0.146–300 mM) and HL4E10 Fab
(0.122–2000 nM) at a flow rate of 30 ml/min with duplicates and in randomizedStructure 19,order using BSA as control for nonspecific binding. For the JAML-CAR exper-
iment, dissociation in buffer was used as regeneration method while, for the
JAML-HL4E10 Fab experiment, regeneration was achieved through a 20 ml
injection of 10 mM glycine (pH 3.0).
Data were analyzed with the BIAevaluation software (BIAcore/GE Health-
care Inc.) and with Scrubber-2 (Biologic Software Inc.). Binding kinetics and
affinity for the JAML-HL4E10 reaction were determined by employing a global,
monoexponential, curve fit of the standard 1:1 Langmuir binding isotherm to
the data. The JAML-CAR reaction exhibited rapid kinetics and some extent
of complex binding behavior. Thus, we analyzed the SPR data in several
different ways. We determined KD from equilibrium binding data of the
JAML-CAR reaction, employed a mono-exponential decay fit to the fast
portion of the dissociation phase to yield Koff, and then derived Kon from the
equation KD = Koff/Kon. We also applied simultaneous Kon/Koff global fitting
procedures to the kinetics data. The standard, mono-exponential, 1:1 Lang-
muir binding isotherm did not yield a satisfying fit to the data, but a complex
model (heterogeneous ligand) resulted in a much better interpretation.
However, equilibrium analysis and kinetic analysis of JAML-CAR SPR data
both gave similar binding parameter values and affinity constants on the
same order of magnitude as those determined previously by analytical
ultracentrifugation.
PI3K-Binding Assays
The 7-17 DETC cell line was cultured in complete RPMI 1640 (Invitrogen) +
10% heat-inactivated FCS + 20 U/ml IL-2 at 37C and 5% CO2. Cells (5 3
106) were seeded into Petri dishes and incubated overnight. On the next
day, the cells were serum- and IL-2 starved for 4 hr at 37C prior to incubation
with 10 mg/ml CAR-Fc fusion protein (Witherden et al., 2010) or HL4E10 IgG in
DPBS. After 5 min incubation at 37C, the cells were washed three times with
ice-cold PBS and lysed in lysis buffer (10mMTris [pH 7.6], 150mMNaCl, 1mM
EDTA, 0.5% NP-40, 1 mM Na3VO4, 1 mM Na2MoO4, 5 mM MgCl2, 1 3
Complete Protease Inhibitor Tablet [Roche]). Full-length JAML was immuno-
precipitated from lysate volumes corresponding to 200 mg total protein using
25 ml Protein A beads and 5 mg purified anti-JAML HL4E10 IgG for at least
3 hr at 4C under agitation. Beads were washed four times with 0.5 ml lysis
buffer, and 25 ml 2 3 reducing sample loading buffer was added. After gently
vortexing and boiling for 5 min at 100C, the supernatants were collected by
centrifugation and proteins separated by SDS-PAGE. Proteins were blotted
onto a nitrocellulose membrane, blocked with 10% goat serum, 3% BSA for
2 hr at room temperature, and probed over night at 4C with rabbit anti-PI3K
p85 mAb 19H8 (Cell Signaling Technology). HRP-conjugated goat anti-rabbit
IgG (Southern Biotechnology) was used as secondary antibody and the signal
was developed in Supersignal West Pico ECL (Pierce).
Cell Proliferation Assays
Purified mAb IgGs and Fabs were diluted in ELISA coating buffer (50 mM Tris,
150 mM NaCl [pH 8.0] at room temperature) and immobilized to individual
wells of 96-well, flat-bottom, microtiter ELISA plates in a final volume of
100 ml. The plates were incubated at 4C overnight. Before adding cells, the
plates were washed twice with ELISA coating buffer and blocked for 15 min
with 100 ml complete DMEM media (Invitrogen) supplemented with 10%
heat-inactivated FCS. 7-17 DETCswere cultured at 53 104 cells per well. Cells
were pulsed with 1 mCi 3H-thymidine at 24 hr after initiation of culture and
harvested 14 hr later. Cells were harvested onto glass fiber filters (Cambridge
Technology), and 2 ml scintillation fluid was added to each sample. Counts
were read on a Beckman LS3801 scintillation counter (Beckman Coulter). All
data points were performed in triplicate and are presented as mean ± SD.
Sequence Analysis
Protein sequence homologs of mouse JAML (GenBank entries: mouse,
NM_001005421; rat, XM_236198; pig, AK238962; cattle, NM_001080250;
dog, XM_848338; horse, XM_001502755; human, NM_153206; chimpanzee,
XM_508787; rhesus monkey, XM_001093298; platypus, XM_001519842;
gray short-tailed opossum, XM_001380707; red jungle fowl, XM_417915)
and mouse CAR (GenBank entries: mouse, NM_009988; rat, NM_053570;
chimpanzee, XM_531394; dog, XM_535566; human, AF124598; rabbit,
EF034116; orangutan, NM_001134075; rhesus monkey, XM_001107115;
horse, XM_001497763; pig, XM_001924554; gray short-tailed opossum,80–89, January 12, 2011 ª2011 Elsevier Ltd All rights reserved 87
Structure
Structure of the JAML-HL4E10 Antibody ComplexXM_001369028; platypus, XM_001519711; red jungle fowl, XM_416681;
western clawed frosh, NM_001011084; African clawed frosh,
NM_001112833; zebrafish, BC164203) were retrieved with tBLASTn (Altschul
et al., 1990) and aligned and manually edited with BIOEDIT (Hall, 1999).
ACCESSION NUMBERS
The coordinates and structure factors of the JAML-HL4E10 complex have
been deposited in the Protein Data Bank with accession number 3MJ9.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and can be found with this
article online at doi:10.1016/j.str.2010.10.007.
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